RadNet Inc announced its participation in a clinical trial to evaluate the biomarker effects of the investigational drug E2609, a BACE inhibitor, which is being developed for the potential disease modifying treatment of Alzheimer’s disease (AD). Multiple RadNet imaging centers will provide the MRI and beta-amyloid positron emission tomography/computed tomography (PET/CT) capabilities for the clinical trial. The sites are located in Los Angeles and Baltimore.

The Phase 1 trial will explore whether E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor, discovered and developed by Eisai Co, Ltd, changes the levels of beta-amyloid in patients identified as having subjective memory complaints and mild cognitive impairment or mild dementia due to Alzheimer’s disease.